Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients. Issue 4 (9th April 2022)

• Record Type: Journal Article
• Authors: Gori, Mauro; Berzuini, Carlo; D'Elia, Emilia; Ghirardi, Arianna; Bernardinelli, Luisa; Gavazzi, Antonello; Balestrieri, Giulio; Giammarresi, Andrea; Trevisan, Roberto; Di Marco, Fabiano; Bellasi, Antonio; Amoroso, Mariangela; Raimondi, Federico; Novelli, Luca; Magro, Bianca; Mangia, Gianpaolo; Lorini, Ferdinando L.; Guagliumi, Giulio; Fagiuoli, Stefano; Parati, Gianfranco; Senni, Michele
• Is Part Of: Journal of hypertension. Volume 40:Issue 4(2022)
• Page Start: 666
• Page End: 674
• Publication Date: 2022-04-09
• Subjects: angiotensin receptor blockers -- angiotensin-converting enzyme inhibitors -- Covid-19 -- elderly -- hypertension -- observational study -- propensity score matching -- renin-angiotensin-system inhibitors; Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/HJH.0000000000003059
• Languages: English
• ISSNs: 1473-5598

Abstract

Abstract : Objectives: The effect of renin-angiotensin system inhibitors (RASIs) on mortality in patients with coronavirus disease (Covid-19) is debated. From a cohort of 1352 consecutive patients admitted with Covid-19 to Papa Giovanni XXIII Hospital in Bergamo, Italy, between February and April 2020, we selected and studied hypertensive patients to assess whether antecedent (prior to hospitalization) use of RASIs might affect mortality from Covid-19 according to age. Methods and results: Arterial hypertension was present in 688 patients. Overall mortality (in-hospital or shortly after discharge) was 35% ( N = 240). After adjusting for 26 medical history variables via propensity score matching, antecedent use of RASIs ( N = 459, 67%) was associated with a lower mortality in older hypertensive patients (age above the median of 68 years in the whole series), whereas no evidence of a significant effect was found in the younger group of the same population ( P interaction = 0.001). In an analysis of the subgroup of 432 hypertensive patients older than 68 years, we considered two RASI drug subclasses, angiotensin-converting enzyme inhibitors (ACEIs, N = 156) and angiotensin receptor blockers (ARBs, N = 140), and assessed their respective effects by taking no-antecedent-use of RASIs as reference. This analysis showed that both antecedent use of ACEIs and antecedent use of ARBs were associated with a lower Covid-19 mortality (odds ratioACEI = 0.57, 95% confidence interval 0.36--0.91, P = 0.018) (odds ratioARB = 0.49, 95% confidence interval 0.29--0.82, P = 0.006). Conclusion: In the population of over-68 hypertensive Covid-19 patients, antecedent use of ACEIs or ARBs was associated with a lower all-cause mortality, whether in-hospital or shortly after discharge, compared with no-antecedent-use of RASIs.